FOXG1 syndrome due to 14q12 microdeletion

FOXG1 syndrome due to 14q12 microdeletion is a rare neurodevelopmental disorder caused by a chromosomal deletion on the long arm of chromosome 14 (region 14q12) that encompasses the FOXG1 gene. FOXG1 (Forkhead Box G1) is a transcription factor critical for early brain development, particularly the forebrain. Loss of this gene through microdeletion leads to a severe congenital brain disorder sometimes referred to as the congenital variant of Rett syndrome or FOXG1-related encephalopathy. The condition primarily affects the central nervous system and is characterized by severe intellectual disability, postnatal microcephaly (reduced head growth after birth), absent or very limited speech, and significant motor impairment including poor voluntary hand use and movement abnormalities such as dyskinesia and hyperkinetic movements. Key clinical features include early-onset seizures, stereotypic hand movements, poor social interaction, irritability, and feeding difficulties. Brain MRI typically reveals structural abnormalities including simplified gyral pattern, hypoplasia or agenesis of the corpus callosum, and delayed myelination. Many affected children also exhibit strabismus and visual impairment. The severity of symptoms can vary depending on the size of the deletion and whether additional genes are involved. Symptoms are typically apparent from early infancy, with developmental milestones being significantly delayed or absent from the outset. There is currently no cure or disease-specific treatment for FOXG1 syndrome due to 14q12 microdeletion. Management is supportive and multidisciplinary, involving neurologists, physiotherapists, occupational therapists, speech therapists, and other specialists. Antiepileptic medications are used to manage seizures, and nutritional support may be needed for feeding difficulties. Physical therapy and assistive devices can help optimize mobility and communication. Ongoing research into FOXG1-related disorders, including gene therapy approaches, is underway but remains in early stages.

Common questions about FOXG1 syndrome due to 14q12 microdeletion